Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Incidence of early anxiet… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Incidence of early anxiety aggravation in trials of selective serotonin reuptake inhibitors in depression

Artikel i vetenskaplig tidskrift
Författare Jakob Näslund
Fredrik Hieronymus
Johan Fredrik Emilsson
Alexander Lisinski
Staffan Nilsson
Elias Eriksson
Publicerad i Acta Psychiatrica Scandinavica
Volym 136
Nummer/häfte 4
Sidor 343-351
ISSN 0001-690X
Publiceringsår 2017
Publicerad vid Institutionen för matematiska vetenskaper
Institutionen för neurovetenskap och fysiologi, sektionen för farmakologi
Sidor 343-351
Språk en
Länkar doi.org/10.1111/acps.12784
Ämnesord adverse events, antidepressants, anxiety, depression, mega-analysis, selective serotonin reuptake inhibitors
Ämneskategorier Psykiatri, Farmakologi

Sammanfattning

© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd Objective: Selective serotonin reuptake inhibitors (SSRIs) may aggravate anxiety and agitation during the first days of treatment but the frequency of such reactions remains unknown. Method: We analysed patient-level data from placebo-controlled trials of sertraline, paroxetine or citalopram in depressed adults. Somatic anxiety, psychic anxiety and psychomotor agitation as assessed using the Hamilton Depression Rating Scale (HDRS) were analysed in all trials (n = 8262); anxiety-related adverse events were analysed in trials investigating paroxetine and citalopram (n = 5712). Results: After one but not two weeks, patients on an SSRI were more likely than those on placebo to report enhanced somatic anxiety (adjusted risk 9.3% vs. 6.7%); likewise, mean rating of somatic anxiety was higher in the SSRI group. In contrast, patients receiving an SSRI were less likely to report aggravation of psychic anxiety (adjusted risk: 7.0% vs. 8.5%) with mean rating of psychic anxiety and agitation being lower in the SSRI group. The adverse event ‘nervousness’ was more common in patients given an SSRI (5.5% vs. 2.5%). Neither aggravation of HDRS-rated anxiety nor anxiety-related adverse events predicted poor antidepressant response. Conclusion: Whereas an anxiety-reducing effect of SSRIs is notable already during the first week of treatment, these drugs may also elicit an early increase in anxiety in susceptible subjects that however does not predict a poor subsequent response to treatment.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?